Preliminary Recommendation for the Non-Inclusion of Pertuzumab for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Document link: Preliminary Recommendation on Pertuzumab for HER2+ breast cancer (Proponents may submit appeals to hta@doh.gov.ph until 04 February 2022.) Document Preview:
Evidence brief for 10 January – 16 January 2022
For the period of 10 January 2022 to 16 January 2022 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: https://bit.ly/EvidenceBrief_10-16January2022
Evidence brief for 02 January – 07 January 2022
For the period of 02 January 2021 to 07 January 202 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 02 January – 07 December 2022
[Department Personnel Order No. 2021-3184] Appointment of the New Member of the Health Technology Assessment Council Subcommittee on Preventive and Promotive Health
Read more here: ALETH THERESE L. DACANAY, PH.D